Can Precision Oncology Benefit Patients With Cancers of Unknown Primary?-Reference-Cited by-同舟云学术

Can Precision Oncology Benefit Patients With Cancers of Unknown Primary?

Published:2023-09-04 Issue:10 Volume:28 Page:829-831
ISSN:1083-7159
Container-title:The Oncologist
language:en
Short-container-title:

Author:

Rassy Elie¹²^ORCID,Andre Fabrice¹³

Affiliation:

1. Gustave Roussy, Départements de Médecine Oncologique, F-94805 , Villejuif , France

2. CESP, INSERM U1018, Université Paris-Saclay , Villejuif , France

3. Gustave Roussy, INSERM U981, Université Paris-Saclay , Villejuif , France

Abstract

This editorial calls for a strategic shift in our approach to cancers of unknown primary (CUP), one that generates a comprehensive multidimensional portrait of cancer in patients with CUP, to model the biology at the individual level and identify the right therapeutic target accordingly. The framework of this approach is based on the integration of basic biology, biotechnologies, data sciences, clinical research, and social sciences.

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

https://academic.oup.com/oncolo/article-pdf/28/10/829/51821301/oyad248.pdf

Reference14 articles.

1. Hallmarks of cancer: new dimensions;Hanahan,2022

2. Commentary on “tumor heterogeneity and the biology of cancer invasion and metastasis.”;Fidler,2016

3. Not only tumor but also therapy heterogeneity;Garattini;Ann Oncol,2018

4. Precision oncology: who, how, what, when, and when not;Schwartzberg,2017

5. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group;Mosele,2020

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular guided therapies: a practice-changing step forward in cancer of unknown primary management;The Lancet;2024-08

2. Predicting tumour origin with cytology-based deep learning: hype or hope?;Nature Reviews Clinical Oncology;2024-05-21